Graphical abstract
Keywords
Categories
How to Cite
Abstract
Background: Although SNORD3A has been implicated in cancer progression, its specific roles and underlying mechanisms in gastric cancer (GC) remain poorly understood. We analysed SNORD3A expression using TCGA data and evaluated patient survival via Kaplan‒Meier curves. Additionally, we conducted GO-KEGG enrichment analysis to identify relevant biological processes and signaling pathways, while ssGSEA was used to assess the correlation between SNORD3A and cancer immune infiltrates. Furthermore, we explored the relationship between SNORD3A and immunotherapy response through TIDE. We verified SNORD3A expression using real-time qPCR and assessed cell proliferation, migration, and invasion via CCK8 and Transwell migration and invasion assays.
Results: Our results revealed that SNORD3A was significantly upregulated in GC, with high expression correlating with poor survival. SNORD3A and related genes were primarily enriched in the insulin/insulin-related growth factor signaling pathway. We also observed negative associations between SNORD3A expression and several immune cells, including activated dendritic cells, CD56bright natural killer cells, central memory CD8 T cells, effector memory CD8 T cells, effector memory CD4 T cells, eosinophils, immature dendritic cells, macrophages, mast cells, MDSCs, memory B cells, monocytes, neutrophil cells, plasmacytoid dendritic cells, regulatory T cells, and T follicular helper cells. High SNORD3A expression also correlated with a poorer response to immunotherapy. Finally, inhibition of SNORD3A suppressed cell proliferation, migration, and invasion.
Conclusions: Our findings suggest that SNORD3A plays a catalytic role in the proliferation, migration and invasiveness of GC and may have potential as a diagnostic biomarker and therapeutic target for GC.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209-249. https://doi.org/10.3322/caac.21660. PMID:33538338
Ajani JA, D'Amico TA, Bentrem DJ, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022;20(2):167-192. https://doi.org/10.6004/jnccn.2022.0008. PMID:35130500
Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet 2020;396(10251):635-648. https://doi.org/10.1016/s0140-6736(20)31288-5. PMID:32861308
Tsao SW, Tsang CM, Pang PS, et al. The biology of EBV infection in human epithelial cells. Semin Cancer Biol 2012;22(2):137-43. https://doi.org/10.1016/j.semcancer.2012.02.004. PMID:22497025
Li GZ, Doherty GM, Wang J. Surgical Management of Gastric Cancer: A Review. JAMA Surg 2022;157(5):446-454. https://doi.org/10.1001/jamasurg.2022.0182. PMID:35319717
Alsina M, Arrazubi V, Diez M, et al. Current developments in gastric cancer: from molecular profiling to treatment strategy. Nat Rev Gastroenterol Hepatol 2022. https://doi.org/10.1038/s41575-022-00703-w. PMID:36344677
Zhang X, Wang C, Xia S, et al. The emerging role of snoRNAs in human disease. Genes & diseases 2023;10(5):2064-2081. https://doi.org/10.1016/j.gendis.2022.11.018. PMID:MEDLINE:37492704
Roychowdhury A, Samadder S, Das P, et al. Deregulation of H19 is associated with cervical carcinoma. Genomics 2020;112(1):961-970. https://doi.org/10.1016/j.ygeno.2019.06.012. PMID:31229557
Luo L, Zhang J, Tang H, et al. LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death Dis 2020;11(5):329. https://doi.org/10.1038/s41419-020-2557-2. PMID:32382150
Godel M, Morena D, Ananthanarayanan P, et al. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma. Int J Mol Sci 2020;21(12). https://doi.org/10.3390/ijms21124500. PMID:32599901
Luo LY, Zhang JL, Tang HL, et al. LncRNA SNORD3A specifically sensitizes breast cancer cells to 5-FU by sponging miR-185-5p to enhance UMPS expression. Cell Death & Disease 2020;11(5). https://doi.org/10.1038/s41419-020-2557-2. PMID:WOS:000533894200007
Wang G, Lu M, Yao Y, et al. Esculetin exerts antitumor effect on human gastric cancer cells through IGF-1/PI3K/Akt signaling pathway. Eur J Pharmacol 2017;814(207-215. https://doi.org/10.1016/j.ejphar.2017.08.025. PMID:28847482
Guo C, Chu H, Gong Z, et al. HOXB13 promotes gastric cancer cell migration and invasion via IGF-1R upregulation and subsequent activation of PI3K/AKT/mTOR signaling pathway. Life Sci 2021;278(119522. https://doi.org/10.1016/j.lfs.2021.119522. PMID:33894267
Kim R, An M, Lee H, et al. Early Tumor-Immune Microenvironmental Remodeling and Response to First-Line Fluoropyrimidine and Platinum Chemotherapy in Advanced Gastric Cancer. Cancer Discov 2022;12(4):984-1001. https://doi.org/10.1158/2159-8290.Cd-21-0888. PMID:34933901
Shi T, Zhang Y, Wang Y, et al. DKK1 Promotes Tumor Immune Evasion and Impedes Anti-PD-1 Treatment by Inducing Immunosuppressive Macrophages in Gastric Cancer. Cancer Immunol Res 2022;10(12):1506-1524. https://doi.org/10.1158/2326-6066.Cir-22-0218. PMID:36206576
Gambardella V, Castillo J, Tarazona N, et al. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treat Rev 2020;86(102015. https://doi.org/10.1016/j.ctrv.2020.102015. PMID:32248000
Saisana M, Griffin SM, May FEB. Importance of the type I insulin-like growth factor receptor in HER2, FGFR2 and MET-unamplified gastric cancer with and without Ras pathway activation. Oncotarget 2016;7(34):54445-54462. https://doi.org/10.18632/oncotarget.10642. PMID:WOS:000385435000029
Choi YJ. Insulin Resistance: A Hidden Risk Factor for Gastric Cancer? Gut and Liver 2019;13(2):133-134. https://doi.org/10.5009/gnl19060. PMID:WOS:000461020800001
Lee JS, Lero MW, Mercado-Matos J, et al. The insulin and IGF signaling pathway sustains breast cancer stem cells by IRS2/PI3K-mediated regulation of MYC. Cell Rep 2022;41(10):111759. https://doi.org/10.1016/j.celrep.2022.111759. PMID:36476848
Zhen N, Gu S, Ma J, et al. CircHMGCS1 Promotes Hepatoblastoma Cell Proliferation by Regulating the IGF Signaling Pathway and Glutaminolysis. Theranostics 2019;9(3):900-919. https://doi.org/10.7150/thno.29515. PMID:30809316
Du J, Shi HR, Ren F, et al. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells. BMC Cancer 2017;17(1):851. https://doi.org/10.1186/s12885-017-3840-1. PMID:29241458
Saisana M, Griffin SM, May FEB. Insulin and the insulin receptor collaborate to promote human gastric cancer. Gastric Cancer 2022;25(1):107-123. https://doi.org/10.1007/s10120-021-01236-y. PMID:34554347
Jeong I, Kang SK, Kwon WS, et al. Regulation of proliferation and invasion by the IGF signalling pathway in Epstein-Barr virus-positive gastric cancer. J Cell Mol Med 2018;22(12):5899-5908. https://doi.org/10.1111/jcmm.13859. PMID:30247804
Zavros Y, Merchant JL. The immune microenvironment in gastric adenocarcinoma. Nat Rev Gastroenterol Hepatol 2022;19(7):451-467. https://doi.org/10.1038/s41575-022-00591-0. PMID:35288702
Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin 2021;71(3):264-279. https://doi.org/10.3322/caac.21657. PMID:33592120
Lei ZN, Teng QX, Tian Q, et al. Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduct Target Ther 2022;7(1):358. https://doi.org/10.1038/s41392-022-01190-w. PMID:36209270
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Electronic Journal of Biotechnology